ScholarIQanswers from OpenAlex & ORCID
Ronald Feld
ResearcherPublications, citations & collaboration network
Ronald Feld is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ronald Feld have?
ScholarIQindexed works
Ronald Feld has 302 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ronald Feld have?
ScholarIQcitation count
Ronald Feld has 18,518 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ronald Feld?
ScholarIQh-index
Ronald Feld has an h-index of 68 in OpenAlex.
What is the i10-index of Ronald Feld?
ScholarIQi10-index
Ronald Feld has an i10-index of 175 in OpenAlex.
What is the OpenAlex record for Ronald Feld?
ScholarIQopenalex
The OpenAlex for Ronald Feld is on the source record.
What are the most-cited papers on Ronald Feld?
ScholarIQmost cited works
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
E Rapp, Joseph L. Pater, Andrew R. Willan, Yvon Cormier, Nevin Murray, William K. Evans, D. Ian Hodson, DavidA. Clark, Ronald Feld, Andrew Arnold
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Ronald Feld, Charles Butts, Vittorio Gebbia, Paolo Maione, Floriana Morgillo, Giovenzio Genestreti, Adolfo Favaretto, Natasha B. Leighl, Rafal Wierzbicki, Saverio Cinieri, Yasmin Alam, Salvatore Siena, Giampaolo Tortora, Raffaella Felletti, Ferdinando Riccardi, Gianfranco Mancuso, Antônio Rossi, Flavia Cantile, Ming‐Sound Tsao, Mauro Saieg, Gilda da Cunha Santos, Maria Carmela Piccirillo, Massimo Di Maïo, Alessandro Morabito, Francesco Perrone